Microsurgical Treatment of Epilepsy with Parenchymal Neurocysticercosis

Abstract

Parenchymal neurocysticercosis is the most common form of neurocysticercosis in the central nervous system (CNS), which mainly causes epilepsy and usually responses well to routine medications. However, there are appreciable cases of relapses refractory to medical treatment. We investigated microsurgical treatment of epilepsy with parenchymal neurocysticercosis. Nine cases of epilepsy caused by parenchymal neurocysticercosis from 2002 to 2018 were analyzed retrospectively. Cysts in 7 cases were completely removed. No case died of operation and no new dysfunction of the nervous system was observed after surgery. Among the other 9 cases, 8 cases became seizure-free or controlled by medicine according to the postoperative follow-up for 6 months to 9 years. One case was lost for follow-up. It was suggested that epilepsy with parenchymal neurocysticercosis can usually be controlled after routine medications. However, surgery is still indicated in some cases and careful microsurgery is associated with satisfactory clinical outcomes in appropriately selected cases.

Keywords

epilepsy / parenchymal cysticercosis / neurocysticercosis / microsurgery

References

[1] ArseniC, CristescuA. Epilepsy due to cerebral cysticercosis. Epilepsia, 1972, 13(2): 253-258

[2] BlythW. Cysticercosis Epilepsy. Br Med J, 1941, 1(4184): 401-402

[3] CarpioA, EscobarA, HauserWA. Cysticercosis and epilepsy: a critical review. Epilepsia, 1998, 39(10): 1025-1040

[4] KaiserC, PionS, PreuxPM, et al.. Onchocerciasis, cysticercosis, and epilepsy. Am J Trop Med Hyg, 2008, 79(5): 643-644

[5] MonteiroL, LopesJ, Martins da SilvaA. Relationship between cysticercosis and epilepsy. Epilepsia, 1999, 40(10): 1464-1465

[6] NicolettiA, BartoloniA, ReggioA, et al.. Epilepsy, cysticercosis, and toxocariasis: a population-based case-control study in rural Bolivia. Neurology, 2002, 58(8): 1256-1261

[7] NsengiyumvaG, Druet-CabanacM, RamanankandrasanaB, et al.. Cysticercosis as a major risk factor for epilepsy in Burundi, east Africa. Epilepsia, 2003, 44(7): 950-955

[8] GarciaHH, Del BruttoOH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol, 2005, 4(10): 653-661

[9] QuetF, GuerchetM, PionSD, et al.. Meta-analysis of the association between cysticercosis and epilepsy in Africa. Epilepsia, 2010, 51(5): 830-837

[10] CarpioA, PlacenciaM, SantillanF, et al.. A proposal for classification of neurocysticercosis. Can J Neurol Sci, 1994, 21(1): 43-47

[11] GarciaHH, EvansCA, NashTE, et al.. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev, 2002, 15(4): 747-756

[12] SinhaS, SharmaBS. Neurocysticercosis: a review of current status and management. J Clin Neurosci, 2009, 16(7): 867-876

[13] Del BruttoOH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology, 1994, 44(9): 1706-1709

[14] NdimubanziPC, CarabinH, BudkeCM, et al.. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis, 2010, 4(11): e870

[15] CarpioA, KelvinEA, BagiellaE, et al.. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry, 2008, 79(9): 1050-1055

[16] SaenzB, RamirezJ, AlujaA, et al.. Human and porcine neurocysticercosis: differences in the distribution and developmental stages of cysticerci. Trop Med Int Health, 2008, 13(5): 697-702

[17] Del BruttoOH. Neurocysticercosis in Western Europe: a re-emerging disease. Acta Neurol Belg, 2012, 112(4): 335-343

[18] GarciaHH. Neurocysticercosis in immigrant populations. J Travel Med, 2012, 19(2): 73-75

[19] SerpaJA, GravissEA, KassJS, et al.. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore), 2011, 90(1): 81-86

[20] SorvilloF, WilkinsP, ShafirS, et al.. Public health implications of cysticercosis acquired in the United States. Emerg Infect Dis, 2011, 17(1): 1-6

[21] HawkMW, ShahlaieK, KimKD, et al.. Neurocysticercosis: a review. Surg Neurol, 2005, 63(2): 123-132

[22] GarciaHH, GilmanR, MartinezM, et al.. Cysticercosis as a major cause of epilepsy in Peru. The Cysticercosis Working Group in Peru (CWG). Lancet, 1993, 341(8839): 197-200

[23] DuqueKR, EscalayaAL, ZapataW, et al.. Clinical topography relationship in patients with parenchymal neurocysticercosis and seizures. Epilepsy Res, 2018, 145: 145-152

[24] LeonA, SaitoEK, MehtaB, et al.. Calcified parenchymal central nervous system cysticercosis and clinical outcomes in epilepsy. Epilepsy Behav, 2015, 43: 77-80

[25] SinghiP, MalhiP, SutharR, et al.. Long-term Cognitive Outcome of Children With Parenchymal Neurocysticercosis: A Prospective Observation Study. J Child Neurol, 2018, 33(7): 468-473

[26] SinghiP, SutharR, DeoB, et al.. Long-term Clinical and Radiologic Outcome in 500 Children with Parenchymal Neurocysticercosis. Pediatr Infect Dis J, 2017, 36(6): 549-555

[27] FleuryA, Carrillo-MezoR, FlisserA, et al.. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther, 2011, 9(1): 123-133

[28] MatushitaH, PintoFC, CardealDD, et al.. Hydrocephalus in neurocysticercosis. Childs Nerv Syst, 2011, 27(10): 1709-1721

[29] SoteloJ. Clinical manifestations, diagnosis, and treatment of neurocysticercosis. Curr Neurol Neurosci Rep, 2011, 11(6): 529-535

[30] RathoreC, ThomasB, KesavadasC, et al.. Calcified neurocysticercosis lesions and hippocampal sclerosis: potential dual pathology. Epilepsia, 2012, 53(4): e60-62

[31] NashTE, PretellEJ, LescanoAG, et al.. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol, 2008, 7(12): 1099-1105

[32] ModakA, SutharR, SharawatIK, et al.. An Ambispective Cohort Study to Assess Seizure Recurrences in Children with Calcified Parenchymal Neurocysticercosis. Am J Trop Med Hyg., 2019, 101(4): 812-820

[33] Del BruttoOH, RajshekharV, WhiteA J, et al.. Proposed diagnostic criteria for neurocysticercosis. Neurology, 2001, 57(2): 177-183

[34] Del BruttoOH, WadiaNH, DumasM, et al.. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci, 1996, 142(1–2): 1-6

[35] Del BruttoOH. Neurocysticercosis: a review. Sci World J, 2012, 2012: 159

[36] KaurS, SinghiP, SinghiS, et al.. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J, 2009, 28(5): 403-406

[37] MahantyS, ParedesA, MarzalM, et al.. Sensitive in vitro system to assess morphological and biochemical effects of praziquantel and albendazole on Taenia solium cysts. Antimicrob Agents Chemother, 2011, 55(1): 211-217

[38] SoteloJ, EscobedoF, PenagosP. Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol, 1988, 45(5): 532-534

[39] OuSW, WangJ, WangYJ, et al.. Microsurgical management of cerebral parenchymal cysticercosis. Clin Neurol Neurosurg, 2012, 114(4): 385-388

[40] LeblancR, KnowlesKF, MelansonD, et al.. Neurocysticercosis: surgical and medical management with praziquantel. Neurosurgery, 1986, 18(4): 419-427

[41] RajshekharV. Surgical management of neurocysticercosis. Int J Surg, 2010, 8(2): 100-104

[42] LeiT, ShuK, ChenX, et al.. Surgical treatment of epilepsy with chronic cerebral granuloma caused by Schistosoma japonicum. Epilepsia, 2008, 49(1): 73-79

[43] RosenowF, LudersH. Presurgical evaluation of epilepsy. Brain, 2001, 124(Pt9): 1683-1700